Reference Public rare-disease knowledge base

Trial and Study Record

BBP-418 (Ribitol) FORTIFY Trial in LGMD2I/LGMDR9

Phase 3 randomized ribitol trial in FKRP-related LGMD2I/LGMDR9 and the most advanced current interventional program identified in this FKRP research sweep.

TrialTherapy DevelopmentTrial ReadinessFamilies

Key Takeaway

FORTIFY is the main late-stage FKRP-directed ribitol trial in the public record, but its status still needs to be described carefully as ongoing phase 3 work rather than settled treatment evidence.

Why this record matters

  • This is the clearest current reference point for the ribitol arm of the FKRP pipeline.
  • The trial is important for families and clinicians because sponsor updates and regulatory filings can otherwise blur the distinction between study status and treatment availability.
  • A 2026 sponsor-announced NDA filing increases public attention, but it does not replace the need to keep the trial record and dates visible.

Eligibility and participation notes

  • Enrolled participants aged 12 years and older with genetically confirmed LGMD2I/LGMDR9.
  • Used a randomized placebo-controlled design rather than the open-label structure of earlier development.
  • Public interpretation still depends on the trial record, protocol updates, and later peer-reviewed reporting.

Limits and cautions

  • Active phase 3 status means the public evidence story is still evolving.
  • Sponsor communications may move faster than peer-reviewed publication, so dated wording matters.
  • A regulatory filing is not the same thing as approval or universally established benefit.

Primary Sources

Direct links for verification

Back to Trials and Studies

Related Content

Related routes inside the site

Study Record

A Study of Deflazacort (Emflaza®) in Participants With Limb-Girdle Muscular Dystrophy 2I (LGMD2I)

Phase 3 corticosteroid study record evaluating deflazacort in adults with FKRP-related LGMD2I, ultimately terminated early.

Study Record

ATA-100 (Formerly GNT0006) Gene Therapy Trial in Patients With LGMDR9

Phase 1 FKRP gene-transfer trial record for ATA-100, designed to assess safety, pharmacodynamics, and immunogenicity with long-term follow-up.

Study Record

Study of BBP-418 in Patients With LGMD2I

Phase 2 open-label ribitol study in FKRP-related LGMD2I/LGMDR9 that provides the main early clinical development context for the BBP-418 program.